The Japanese pharma’s attention deficit/hyperactivity disorder candidate has shown significant symptom improvements in children and adolescents in two late-stage studies.

With recent high-profile failures, experts say safety concerns and a lack of diversification are hindering the field—but still hold out hope for an approval.

Reviva Pharmaceuticals Holdings said on Monday its lead experimental drug to treat adults with schizophrenia helped reduce disease symptoms in a late-stage study.

GlaxoSmithKline, GSK

The company stated that its cancer drug Jemperli when combined with chemotherapy, met the primary goal of overall survival in patients with advanced or recurrent endometrial cancer in a late-stage trial.

Alnyam

Following the regulator’s denial of patisiran’s label expansion, Alnylam has published late-stage data for the RNAi therapeutic in The New England Journal of Medicine demonstrating its efficacy in ATTR-cardiomyopathy.

Pfizer

“This vaccine has the potential to lessen the impact of two respiratory diseases with a single injection and may simplify immunization practices,” Annaliesa Anderson, Pfizer’s head of vaccine research and development, said in a statement.

antibody-drug conjugate molecules

The companies presented data from two pivotal studies of Dato-DXd, focusing on safety concerns and survival data for the investigational antibody-drug conjugate candidate in lung and breast cancer.

The coming decades could see an astounding transformation in drug discovery due to AI. But experts say it’s critical to deal now with potential ethical and social justice landmines that may be encountered on the way to this new era.

Klick Health

Klick Labs scientists discover voice tech as potential game changer in Type 2 diabetes detection.

Merck & Co.

The three drug candidates to be developed with Merck belong to the class known as antibody drug conjugates (ADC) and are in various stages of clinical development for the treatment of multiple solid cancer tumors.